Standard of Care COPD Treatment — Competitive Intelligence Brief

Standard of Care COPD Treatment (Standard of Care COPD Treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic antagonist. Area: Respiratory.

phase 3 Muscarinic antagonist M3 muscarinic receptor Respiratory Small molecule

Target snapshot

Standard of Care COPD Treatment (Standard of Care COPD Treatment) — AstraZeneca. Tiotropium bromide is a long-acting muscarinic antagonist that relaxes bronchial smooth muscle and increases lung function in patients with COPD.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard of Care COPD Treatment TARGET	Standard of Care COPD Treatment	AstraZeneca	phase 3	Muscarinic antagonist	M3 muscarinic receptor
Aclidinium bromide & formoterol fumarate	Aclidinium bromide & formoterol fumarate	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg	Revefenacin 175 µg, Formoterol 20 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
fluticasone/salmeterol, tiotropium	fluticasone/salmeterol, tiotropium	Taipei Veterans General Hospital, Taiwan	marketed	Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol); M3 muscarinic receptor (tiotropium)
Umeclidinium/Vilanterol 62.5/25 mcgs	Umeclidinium/Vilanterol 62.5/25 mcgs	National Institute of Respiratory Diseases, Mexico	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Fluticasone furoate/umeclidinium/vilanterol	Fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
Solifenacin with vaginal estrogen cream	Solifenacin with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream)	M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic antagonist class)

1. AstraZeneca · 1 drug in this class
2. Henan University of Traditional Chinese Medicine · 1 drug in this class
3. Novartis · 1 drug in this class